Stifel resumed coverage of Abeona Therapeutics (ABEO) with a Buy rating and $14 price target While acknowledging both the difficult-to-vet nature of CMC-related deliverables highlighted in FDA’s 2024 Complete Response Letter and the recent departure of cell and gene-therapy “champion” Peter Marks from FDA as sources of uncertainty ahead of the April 29 PDUFA date, the firm believes the totality of clinical data generated to date suggests pz-cel offers a unique value proposition as a novel treatment option for patients with recessive dystrophic epidermolysis bullosa, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics announces employee inducement grants
- Abeona Therapeutics: Buy Rating Backed by Imminent FDA Approval and Strong Market Position of Lead Candidate
- Abeona Therapeutics: Positive Outlook Amid FDA Hopes
- Abeona Therapeutics Reports 2024 Financial Results
- Abeona price target raised to $25 from $20 at Alliance Global Partners